Arora Jitesh, Nassar Mahmoud, Baraka Bahaaeldin
Department of Geriatric Medicine, Nottingham University Hospitals NHS Trust, Nottingham NG7 2UH, United Kingdom.
Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, New York, NY 14203, United States.
World J Gastrointest Oncol. 2025 Jun 15;17(6):103333. doi: 10.4251/wjgo.v17.i6.103333.
Esophageal cancer (EC) continues to pose a significant clinical challenge due to the absence of a reliable early detection method, leading to late-stage diagnoses and poor patient outcomes. The recent study by Liu presents a promising breakthrough, demonstrating that plasma DNA methylation markers-SHOX2, SEPTIN9, EPO, and RNF180-offer a non-invasive approach for early EC detection with 76.19% sensitivity and 86.27% specificity. Given the urgent need for effective screening strategies, the potential integration of this assay into clinical practice could significantly enhance early diagnosis, patient monitoring, and overall survival rates. While further validation is necessary, this advancement marks an important step toward improving EC detection and management.
由于缺乏可靠的早期检测方法，食管癌（EC）仍然构成重大的临床挑战，导致晚期诊断和患者预后不佳。刘的最新研究提出了一个有希望的突破，表明血浆DNA甲基化标志物-SHOX2、SEPTIN9、EPO和RNF180-为早期食管癌检测提供了一种非侵入性方法，灵敏度为76.19%，特异性为86.27%。鉴于迫切需要有效的筛查策略，将该检测方法整合到临床实践中可能会显著提高早期诊断、患者监测和总体生存率。虽然还需要进一步验证，但这一进展标志着在改善食管癌检测和管理方面迈出了重要一步。
